X4 Pharmaceuticals (XFOR) Change in Receivables (2020 - 2026)

X4 Pharmaceuticals (XFOR) has reported Change in Receivables for 4 consecutive years, with $934000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables rose 46.86% year-over-year to $934000.0; the trailing twelve-month figure through Jun 2026 stood at $903000.0 (down 21.14% YoY), and the FY2025 full-year result was -$497000.0, down 146.45% from the prior year.
• Change in Receivables climbed to $934000.0 in Q2 2026 per XFOR's latest filing, from $541000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $1.1 million in Q4 2024 and bottomed at -$561000.0 in Q1 2025.
• Historically, Change in Receivables has averaged $292571.4 across 3 years, with a median of $541000.0 in 2026.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables tumbled 129.72% in 2025, then surged 196.43% in 2026.
• Over 3 years, Change in Receivables stood at $1.1 million in 2024, then sank by 129.72% to -$318000.0 in 2025, then jumped by 393.71% to $934000.0 in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $934000.0, $541000.0, and -$318000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.